Literature DB >> 24946815

Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.

A Grey1, A Cooper, C McNeil, S O'Toole, J Thompson, P Grimison.   

Abstract

Vemurafenib is a tyrosine kinase inhibitor of BRAF that prolongs survival in patients with BRAF V600-mutant metastatic melanoma. Secondary cutaneous malignancies are a well-documented toxicity of vemurafenib, thought to be mediated by enhanced ERK signalling in BRAF wild-type, RAS-mutant cells. Vemurafenib could also promote growth of non-cutaneous secondary malignancies by a similar mechanism. We present a case of an individual who received vemurafenib for metastatic melanoma and experienced rapid growth of a pre-existing KRAS-mutant pancreatic adenocarcinoma.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  BRAF inhibitor; melanoma; pancreatic adenocarcinoma; secondary malignancy; vemurafenib

Mesh：

Substances：

Year:  2014        PMID： 24946815     DOI： 10.1111/imj.12415

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


  5 in total

Review 1.  Overcoming resistance to BRAF inhibitors.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Ann Transl Med       Date:  2017-10

Review 2.  Vemurafenib-induced progression of breast cancer: a case report and review of the literature.

Authors:  Aleksei V Novik; Svetlana A Protsenko; Irina A Baldueva; Aleksander O Ivantsov; Tatyana L Nekhaeva; Zinaida Y Akhaeva; Grigoriy A Yanus; Aglaya G Iyevleva; Evgeny N Imyanitov
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

3.  PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.

Authors:  Candani S A Tutuka; Miles C Andrews; John M Mariadason; Paul Ioannidis; Christopher Hudson; Jonathan Cebon; Andreas Behren
Journal:  Mol Cancer       Date:  2017-06-28       Impact factor: 27.401

Review 4.  Clinical Translation of Combined MAPK and Autophagy Inhibition in RAS Mutant Cancer.

Authors:  Jennifer J Lee; Vaibhav Jain; Ravi K Amaravadi
Journal:  Int J Mol Sci       Date:  2021-11-17       Impact factor: 6.208

Review 5.  The evolution of combined molecular targeted therapies to advance the therapeutic efficacy in melanoma: a highlight of vemurafenib and cobimetinib.

Authors:  Theresa M Medina; Karl D Lewis
Journal:  Onco Targets Ther       Date:  2016-06-22       Impact factor: 4.147
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.